Drugs / VB-111
VB-111
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00559117 | Nov 2007 → Jun 2015 | cancer of unknown primary site | Vascular Biogenics Ltd. operating as VBL Therapeutics | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01260506 | Dec 2010 → Jul 2015 | glioblastoma | Vascular Biogenics Ltd. operating as VBL Therapeutics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04166383 | Aug 2020 → Apr 2022 | colorectal carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT01229865 | Dec 2010 → Oct 2014 | differentiated thyroid carcinoma | Vascular Biogenics Ltd. operating as VBL Therapeutics | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03398655 | Dec 2017 → Jul 2022 | — | Vascular Biogenics Ltd. operating as VBL Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT02511405 | Aug 2015 → Nov 2017 | glioblastoma | Vascular Biogenics Ltd. operating as VBL Therapeutics | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VB-111 | “VB-111 (ofranergene obadenovec) is a genetically-modified adenoviral vector targeting the TME” PMID 38184304 ↗ Jan 2024 |
| Known as | Ofra-Vec | “Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).” PMID 37906726 ↗ Oct 2023 |
| Known as | ofranergene obadenovec | “BACKGROUND: Ofranergene obadenovec (VB-111) is an anticancer viral therapy that demonstrated in a phase II study a survival benefit for patients with recurrent glioblastoma...” PMID 31844890 ↗ May 20201“VB-111 (ofranergene obadenovec) is a genetically-modified adenoviral vector targeting the TME” PMID 38184304 ↗ Jan 2024 |
| Known as | Vascular Biogenics (VB)-111 | “Vascular Biogenics (VB)-111 is an anti-angiogenic agent comprising of a nonreplicating E1 deleted adenovirus type 5 which contains a modified murine preproendothelin (PPE)...” NCT04166383 ↗ |
| Modality | Other / unclassified | “antiangiogenic and vascular disruptive agent” NCT01229865 ↗ |
| Route | Intravenous | “intravenously infusion” NCT00559117 ↗ |